Join our daily newsletter At The Bell to receive exclusive market insights
- Recce Pharmaceuticals (RCE) has begun the process to dual list on the Frankfurt Stock Exchange (FSE)
- The company has appointed Deutsche Gesellschaft Für Wertpapieranalyse (DGWA) as its investor and corporate relations advisor in Europe
- DGWA will engage prospective investors and drive awareness of Recce’s products
- Dual listing on the FSE will give Recce exposure to multiple retail and institutional investors in the European Union
- The company will keep the market updated as the listing progresses
- Shares in Recce are steady on the market and are trading at $1.05 per share
Recce Pharmaceuticals (RCE) has begun the process to dual list on the Frankfurt Stock Exchange (FSE).
The FSE is the tenth-largest stock exchange in the world, third-largest in Europe and is owned and operated by Deutsche Börse AG and Börse Frankfurt Zertifikate AG.
Recce has appointed Deutsche Gesellschaft Für Wertpapieranalyse (DGWA) as its investor and corporate relations advisor in Europe.
DGWA will engage prospective investors and drive awareness of Recce’s products.
“We are excited to support Recce in engagement with European investors and opportunities to expand its infectious disease programs,” DGWA CEO Stefan Müller said.
Dual listing on the FSE will give Recce exposure to multiple retail and institutional investors in the European Union.
“Dual listing on the FSE enables Recce to broaden its exposure to European investors,” Chairman Dr John Prendergast said.
“The company considers that it meets the requirement necessary to dual list on the FSE and will provide updates on its application process,” he added.
Recce expects further developments regarding the listing process will be completed in the upcoming weeks.
Shares in Recce are steady on the market and are trading at $1.05 each.
